Oral steroid improves bullous pemphigoid-like clinical manifestations in non-Herlitz junctional epidermolysis bullosa with COL17A1 mutation

E. Mabuchi, Noriko Umegaki, H. Murota, T. Nakamura, K. Tamai, I. Katayama

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Non-Herlitz junctional epidermolysis bullosa (JEB-nH), a nonlethal variant of junctional epidermolysis bullosa (JEB), is an autosomal recessive disorder characterized by separation of the dermal-epidermal junction. JEB-nH is caused by mutations in several genes and lack of the COL17A1 gene product may lead to skin fragility. A 41-year-old Japanese man with JEB-nH, featuring mutations in the gene encoding type XVII collagen, presented with great blisters over his entire body accompanied by severe itching and eosinophilia usually observed in bullous pemphigoid (BP). To our knowledge, our patient is the first with JEB-nH to be treated successfully with an oral steroid to control his skin affliction, symptoms and eosinophilia. This suggests that in the case of JEB-nH with eosinophilia caused by some secondary immune activation, oral steroids may constitute an alternate therapy to improve aggravated skin conditions and severe itching, both of which tend to show resistance to usual dermatological treatments.

Original languageEnglish
Pages (from-to)596-598
Number of pages3
JournalBritish Journal of Dermatology
Volume157
Issue number3
DOIs
Publication statusPublished - 2007 Sep
Externally publishedYes

Fingerprint

Junctional Epidermolysis Bullosa
Bullous Pemphigoid
Steroids
Mutation
Eosinophilia
Skin
Pruritus
Genes
Blister

Keywords

  • Bullous pemphigoid
  • Eosinophilia
  • Non-Herlitz junctional epidermolysis bullosa
  • Oral steroid

ASJC Scopus subject areas

  • Dermatology

Cite this

Oral steroid improves bullous pemphigoid-like clinical manifestations in non-Herlitz junctional epidermolysis bullosa with COL17A1 mutation. / Mabuchi, E.; Umegaki, Noriko; Murota, H.; Nakamura, T.; Tamai, K.; Katayama, I.

In: British Journal of Dermatology, Vol. 157, No. 3, 09.2007, p. 596-598.

Research output: Contribution to journalArticle

Mabuchi, E. ; Umegaki, Noriko ; Murota, H. ; Nakamura, T. ; Tamai, K. ; Katayama, I. / Oral steroid improves bullous pemphigoid-like clinical manifestations in non-Herlitz junctional epidermolysis bullosa with COL17A1 mutation. In: British Journal of Dermatology. 2007 ; Vol. 157, No. 3. pp. 596-598.
@article{5af28f38bbbb41619b9caceafd8d08cb,
title = "Oral steroid improves bullous pemphigoid-like clinical manifestations in non-Herlitz junctional epidermolysis bullosa with COL17A1 mutation",
abstract = "Non-Herlitz junctional epidermolysis bullosa (JEB-nH), a nonlethal variant of junctional epidermolysis bullosa (JEB), is an autosomal recessive disorder characterized by separation of the dermal-epidermal junction. JEB-nH is caused by mutations in several genes and lack of the COL17A1 gene product may lead to skin fragility. A 41-year-old Japanese man with JEB-nH, featuring mutations in the gene encoding type XVII collagen, presented with great blisters over his entire body accompanied by severe itching and eosinophilia usually observed in bullous pemphigoid (BP). To our knowledge, our patient is the first with JEB-nH to be treated successfully with an oral steroid to control his skin affliction, symptoms and eosinophilia. This suggests that in the case of JEB-nH with eosinophilia caused by some secondary immune activation, oral steroids may constitute an alternate therapy to improve aggravated skin conditions and severe itching, both of which tend to show resistance to usual dermatological treatments.",
keywords = "Bullous pemphigoid, Eosinophilia, Non-Herlitz junctional epidermolysis bullosa, Oral steroid",
author = "E. Mabuchi and Noriko Umegaki and H. Murota and T. Nakamura and K. Tamai and I. Katayama",
year = "2007",
month = "9",
doi = "10.1111/j.1365-2133.2007.08046.x",
language = "English",
volume = "157",
pages = "596--598",
journal = "British Journal of Dermatology",
issn = "0007-0963",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Oral steroid improves bullous pemphigoid-like clinical manifestations in non-Herlitz junctional epidermolysis bullosa with COL17A1 mutation

AU - Mabuchi, E.

AU - Umegaki, Noriko

AU - Murota, H.

AU - Nakamura, T.

AU - Tamai, K.

AU - Katayama, I.

PY - 2007/9

Y1 - 2007/9

N2 - Non-Herlitz junctional epidermolysis bullosa (JEB-nH), a nonlethal variant of junctional epidermolysis bullosa (JEB), is an autosomal recessive disorder characterized by separation of the dermal-epidermal junction. JEB-nH is caused by mutations in several genes and lack of the COL17A1 gene product may lead to skin fragility. A 41-year-old Japanese man with JEB-nH, featuring mutations in the gene encoding type XVII collagen, presented with great blisters over his entire body accompanied by severe itching and eosinophilia usually observed in bullous pemphigoid (BP). To our knowledge, our patient is the first with JEB-nH to be treated successfully with an oral steroid to control his skin affliction, symptoms and eosinophilia. This suggests that in the case of JEB-nH with eosinophilia caused by some secondary immune activation, oral steroids may constitute an alternate therapy to improve aggravated skin conditions and severe itching, both of which tend to show resistance to usual dermatological treatments.

AB - Non-Herlitz junctional epidermolysis bullosa (JEB-nH), a nonlethal variant of junctional epidermolysis bullosa (JEB), is an autosomal recessive disorder characterized by separation of the dermal-epidermal junction. JEB-nH is caused by mutations in several genes and lack of the COL17A1 gene product may lead to skin fragility. A 41-year-old Japanese man with JEB-nH, featuring mutations in the gene encoding type XVII collagen, presented with great blisters over his entire body accompanied by severe itching and eosinophilia usually observed in bullous pemphigoid (BP). To our knowledge, our patient is the first with JEB-nH to be treated successfully with an oral steroid to control his skin affliction, symptoms and eosinophilia. This suggests that in the case of JEB-nH with eosinophilia caused by some secondary immune activation, oral steroids may constitute an alternate therapy to improve aggravated skin conditions and severe itching, both of which tend to show resistance to usual dermatological treatments.

KW - Bullous pemphigoid

KW - Eosinophilia

KW - Non-Herlitz junctional epidermolysis bullosa

KW - Oral steroid

UR - http://www.scopus.com/inward/record.url?scp=34547855870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547855870&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2133.2007.08046.x

DO - 10.1111/j.1365-2133.2007.08046.x

M3 - Article

C2 - 17596158

AN - SCOPUS:34547855870

VL - 157

SP - 596

EP - 598

JO - British Journal of Dermatology

JF - British Journal of Dermatology

SN - 0007-0963

IS - 3

ER -